NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer``-;'LLJSAK36I

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

19-C-0104

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male
Min Age: 18
Max Age: 100

Referral Letter Required

No

Population Exclusion(s)

Female;
Children

Special Instructions

Currently Not Provided

Keywords

PSMA;
PET agent;
Prostatectomy;
Progression Free Survival

Recruitment Keyword(s)

None

Condition(s)

Prostate Cancer

Investigational Drug(s)

18FDCFPyl

Investigational Device(s)

None

Intervention(s)

Drug: 18F-DCFPyL

Supporting Site

National Cancer Institute

Background:

People with prostate cancer usually have their cancer imaged with a CT scan and bone scan. They then have their prostate gland removed. Researchers want to test a scan that might predict if prostate cancer will return after this surgery.

Objective:

To test if a PET/CT scan before the prostate gland is removed can predict if prostate cancer will return. Also, to test if this approach is better or worse than the usual approach for prostate cancer.

Eligibility:

Men ages 18 and older with prostate cancer that appears to be contained within the prostate but is at risk of having spread

Design:

Participants will be screened with:

-Medical history

-Blood tests

-CT and MRI scans: Participants will lie in a machine. The machine will take pictures of the body.

-Bone scan

Participants will have a radiotracer injected into a vein. They will have a PET/CT scan of their whole body 60 90 minutes later. During the scan, they will lie on their back and stay still.

Within 60 days after the scan, participants will have surgery. This will remove the prostate gland and lymph nodes around it. Some tissue will be used for genetic testing.

If the PET/CT scan suggests the cancer has spread, participants may need to have another biopsy within 60 days after the scan.

After surgery, participants will have follow-up visits for 5 years. They will have 5 visits the first year and 2 the second. Then they will have visits once a year.

If participants cancer returns, they will have repeat PET/CT scans.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

2.1.1.1 Patients must have histologically proven prostate adenocarcinoma confirmed by a CLIA certified laboratory.

2.1.1.2 Must have prostate cancer with high risk features defined as:

- Gleason 8 and higher OR

- PSA > 20 ng/mL OR

- Clinical stage T3a (i.e. likely extraprostatic extension on MRI) or T3b

2.1.1.3 Patients must be eligible for and must be planning to undergo radical prostatectomy and lymphadenectomy regardless of findings on 18F-DCFPyL PET/CT

2.1.1.4 Men age greater than or equal to 18 years.

2.1.1.5 ECOG performance status <2

2.1.1.6 Patients must have adequate organ and marrow function as defined below:

-Hemoglobin greater than or equal to 9 g/dL

-leukocytes greater than or equal to 3,000/mcL

-platelets greater than or equal to 100,000/mcL

-total bilirubin <2 X normal institutional limits

-AST(SGOT)/ALT(SGPT) less than or equal to 3 X normal institutional limits

-creatinine <2 X normal institutional limits

OR

eGFR greater than or equal to 50 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.

2.1.1.7 Ability of subject to understand and the willingness to sign a written informed consent document.

2.1.1.8 Willingness and ability to undergo biopsy of radiotracer-avid lesion if feasible.

2.1.1.9 Willingness and ability to undergo multiparametric prostate MRI and 18F-DCFPyL PET/CT

EXCLUSION CRITERIA

2.1.2.1 Any investigational agents in the past 28 days prior to enrollment.

2.1.2.2 Clinical stage T4 (tumor invades adjacent structures except seminal vesicles).

2.1.2.3 Distant metastatic disease on conventional imaging studies (computed tomography (CT) of the abdomen and pelvis and 99mTc-methylene diphosphonate bone scan (bone scan)). NaF PET/CT scan cannot substitute for a bone scan. Given lack of specificity of CT for lymph node metastases at lower thresholds (34, 35), pelvic lymph nodes below 2 cm in the short axis are allowed.

2.1.2.4 Any prior hormone therapy used to treat prostate cancer, except limited androgen receptor antagonist therapy, defined as less than or equal to 3 days of treatment. The medication must be discontinued within 5 half-lives of the compound prior to study entry.

2.1.2.5 Any prior therapy for prostate cancer with surgery, radiation, and/or chemotherapy.

2.1.2.6 Contraindication to MRI or PET:

- Patients weighing more than weight limit for the scanner tables or unable to fit within the imaging gantry

- Prior reaction to 18F-DCFPyL

- Patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic device that are not MRI compatible at 3 T

- Severe claustrophobia unresponsive to oral anxiolytics

2.1.2.7 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

2.1.2.8 Other medical conditions deemed by the principal investigator (or associates) to make the subject unsafe/ineligible for the protocol procedures or for radical prostatectomy.

2.1.2.9 A malignancy within the past 3 years for which prostatectomy is a contraindication.

2.1.2.10 Radiotracer administered within 5 half-lives prior to the date of 18F-DCFPyL PET/CT imaging.

2.1.2.11 PSMA-targeted imaging within 6 months prior to the date of 18F-DCFPyL PET/CT imaging.

2.1.2.12 Unable to refrain from fathering a child or donating sperm for 10 days after each 18FDCFPyL injection.

2.1.3 Recruitment Strategies


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

William L. Dahut Jr., M.D.
National Cancer Institute (NCI)



Guinevere Chun, R.N.
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 12N226
10 Center Drive
Bethesda, Maryland 20892
(240) 760-7967
gchun@mail.nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937

Clinical Trials Number:

NCT03976843

--Back to Top--